Xconomy
OCTOBER 7, 2016
—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. —Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy. .
Xconomy
NOVEMBER 4, 2019
An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JULY 15, 2016
After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. CEO Jeff Jonas told Xconomy previously that positive results could encourage Sage to dive deeper into studying mood disorders—from panic attacks to post-traumatic stress disorder. —With $1.25
Xconomy
JANUARY 25, 2019
After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.
Expert insights. Personalized for you.
77 
Let's personalize your content